NDA 009190 · Guerbet
Lipiodol
Ethiodized Oil · Intralymphatic, Intrauterine · Radiographic Contrast Agent
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Apr 5, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1954
Mar 31, 1954
Approved uses
2
Original approval plus efficacy supplements
Registered trials
119
33 Phase 3, 20 recruiting
FAERS reports
1,298
1,258 serious, 154 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: FOR INTRALYMPHATIC, INTRAUTERINE AND SELECTIVE HEPATIC INTRA-ARTERIAL USE ONLY Pulmonary and cerebral embolism can result from inadvertent intravascular injection or intravasation of Lipiodol. Inject Lipiodol slowly with radiologic monitoring; do not exceed recommended dose ( 5.1 ). WARNING: FOR INTRALYMPHATIC, INTRAUTERINE AND SELECTIVE HEPATIC INTRA-ARTERIAL USE ONLY See Full Prescribing Information for complete Boxed Warning Pulmonary and cerebral embolism can result from inadvertent intravascular injection or intravasation of Lipiodol. Inject Lipiodol slowly with radiologic monitoring; do not exceed recommended dose ( 5.1 ).
What it is approved for
From the label in effect Dec 16, 2025.
Lipiodol is an oil-based radio-opaque contrast agent indicated for: hysterosalpingography in adults lymphography in adult and pediatric patients selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC) Lipiodol is an oil-based radiopaque contrast agent indicated for: hysterosalpingography in adults lymphography in adult and pediatric patients selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC)
Mechanism: Lipiodol opacifies vessels and body structures in the path of the flow of the contrast medium, permitting visualization of the internal structures.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 4, 2014 Supplement 24 · Efficacy LabelLetter
- Mar 31, 1954 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- LIPIODOL · ETHIODIZED OIL EQ 4.8GM IODINE/10ML (EQ 480MG IODINE/ML) · OIL, INTRALYMPHATIC, INTRAUTERINE · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ethiodized Oil" as an intervention, any sponsor and status, largest first.
International Peace Maternity and Child Health HospitalAcademic, hospital or other
NCT06639152 · 1,187 participants · Start May 4, 2020 · Primary completion Aug 30, 2023
Drug: oil-based contrast medium; water-based contrast medium · For: Infertility
Sites: Shanghai, China
- RCT of Ethiodized Poppyseed Oil VS the Second-generation Non-ionic Monomer Contrast in Hysterosalpingography of Infertile Patients.Pivotal-lookingStatus unknown
Guangzhou Women and Children's Medical CenterAcademic, hospital or other
NCT03370575 · 900 participants (planned) · Start Jan 31, 2018 · Primary completion May 1, 2019
Drug: ethiodized poppyseed oil; the second-generation non-ionic monomer contrast · For: Infertility, Female
Sites: Beijing, China; Lanzhou, China; Guangzhou, China · 13 sites in all
- Live Birth After Additional Tubal Flushing With Oil-based Contrast Versus no Additional Flushing:Pivotal-lookingActive, not recruiting
Dafne BalemansAcademic, hospital or other
NCT04379973 · 736 participants (planned) · Start May 25, 2021 · Primary completion Jun 1, 2027
Drug: Lipiodol Ultra Fluide® · For: Infertility, Female
Sites: Antwerp, Belgium; Bonheiden, Belgium; Brasschaat, Belgium · 16 sites in all
- What is the Best Moment for Performing an HSG in Women With a Unfulfilled ChildwishPivotal-lookingStatus unknown
Amsterdam UMC, location VUmcAcademic, hospital or other
NCT05608590 · 554 participants (planned) · Start Aug 22, 2019 · Primary completion Dec 1, 2025
Drug: Lipiodol UltraFluid · For: Female Infertility
Sites: Amsterdam, Netherlands
- Trial of Transcatheter Arterial Chemoembolization for Hepatocellular CarcinomaPivotal-lookingStatus unknown
Nihon UniversityAcademic, hospital or other
NCT00843934 · 450 participants (planned) · Start Mar 2009 · Primary completion Dec 2012
Drug: epirubicin; Cisplatin · For: Carcinoma, Hepatocellular
Sites: tabashi City, Japan
- A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver ResectionPivotal-lookingCompleted
Eastern Hepatobiliary Surgery HospitalAcademic, hospital or other
NCT00820053 · 450 participants · Start Jan 2009 · Primary completion Dec 2009
Drug: epirubicin and lipiodol · For: Hepatocellular Carcinoma
Sites: Shanghai, China
- Adjuvant TACE in HCC With High-risk Recurrence FactorsPivotal-lookingRecruiting
Guangxi Medical UniversityAcademic, hospital or other
NCT07417397 · 442 participants (planned) · Start Feb 1, 2026 · Primary completion Dec 31, 2029
Drug: Adjuvant transarterial chemoembolization · For: Hepatocellular Carcinoma; Adjuvant; Transarterial Chemoembolization
Sites: Nanning, China
- RCT of TAE Simultaneously Combined Thermal Ablation for Large Hepatocellular CarcinomaPivotal-lookingStatus unknown
Sun Yat-sen UniversityAcademic, hospital or other
NCT02964260 · 410 participants (planned) · Start May 2016 · Primary completion Dec 2022
Drug: Chemotherapy drug; Embolic agents · For: Hepatocellular Carcinoma, Adult
Sites: Guangzhou, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product use in unapproved indication294
- off label use170
- liver abscess73
- pyrexia59
- pulmonary embolism49
- product use issue43
- aspartate aminotransferase increased40
- pancytopenia36
- alanine aminotransferase increased35
- disease progression33
- overdose31
- hepatic artery stenosis30
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2006 | 6 |
| 2007 | 3 |
| 2008 | 3 |
| 2009 | 8 |
| 2010 | 7 |
| 2011 | 29 |
| 2012 | 26 |
| 2013 | 25 |
| 2014 | 25 |
| 2015 | 64 |
| 2016 | 82 |
| 2017 | 109 |
| 2018 | 123 |
| 2019 | 97 |
| 2020 | 76 |
| 2021 | 64 |
| 2022 | 67 |
| 2023 | 86 |
| 2024 | 144 |
| 2025 | 109 |
| 2026 | 143 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of CalliSpheres® drug-loaded microspheres combined with doxorubicin in hepatocellular carcinoma.
Jin B, Gu Y, Xi S, et al. · Scand J Gastroenterol 2024 · Randomized Controlled Trial
- The impact of prolonged, maternal iodine exposure in early gestation on neonatal thyroid function.
Mathews DM, Peart JM, Sim RG, et al. · Front Endocrinol (Lausanne) 2023 · Clinical Trial, Research Support, Non-U.S. Gov't
- Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial.
Fan W, Zhu B, Chen S, et al. · JAMA Oncol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Systematic review and meta-analysis of adjuvant i(131) lipiodol after excision of hepatocellular carcinoma.
Furtado R, Crawford M, Sandroussi C · Ann Surg Oncol 2014 · Meta-Analysis, Systematic Review
- Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.
Li QJ, He MK, Chen HW, et al. · J Clin Oncol 2022 · Clinical Trial, Phase III, Comparative Study
- Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies.
Marelli L, Stigliano R, Triantos C, et al. · Cancer Treat Rev 2006 · Meta-Analysis
Sponsor: Guerbet
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.